1751 RIVER RUN, FORT WORTH, TX
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Annual Meeting Results: Directors Elected and Auditor Ratified
Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
Announces Key Appointment of Industry Veteran to Board of Directors
Annual Report to Security Holders
Actuate Therapeutics Shows Positive Phase 2 Results for Elraglusib in Pancreatic Cancer at ASCO GI 2026
Actuate Therapeutics Enters $100 Million At The Market Issuance Agreement
Other Events
Q1
FY 2025
Q3
FY 2024
Q2
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Amended Form D Notice of Exempt Offering of Securities